Efficacy and safety of linagliptin as monotherapy or add-on treatment in Asian patients with suboptimal glycemic control: a pooled analysis
- 8 October 2014
- journal article
- research article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 31 (1), 99-106
- https://doi.org/10.1185/03007995.2014.964856
Abstract
AIMS:\ud To evaluate the efficacy and safety of the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin in Asian patients with type 2 diabetes mellitus (T2DM), a rapidly increasing population.\ud \ud METHODS:\ud Data were pooled for Asian patients receiving linagliptin orally once daily, as monotherapy or added to existing oral antidiabetes therapies, in multinational randomized placebo-controlled clinical trials. Efficacy data were taken from four pivotal trials with 24-week durations to allow for robust efficacy assessment. Safety data were pooled from a wider group of 10 trials with varying durations to capture the largest possible incidence of adverse events (AEs). The primary efficacy endpoint was change from baseline to week 24 in HbA1c. AEs were analyzed descriptively.\ud \ud RESULTS:\ud Mean baseline HbA1c (±SD) in this population was 8.2 ± 0.9%. Placebo-corrected mean change in HbA1c after 24 weeks was -0.79% (95% confidence interval [CI]: -0.92 to -0.67; p < 0.0001). Placebo-corrected mean change in fasting plasma glucose was -17.8 ± 2.4 mg/dL (95% CI: -22.6, -13.0; p < 0.0001). In a small subgroup, mean post-prandial glucose was reduced by a placebo-corrected -56.9 ± 14.0 mg/dL (95% CI: -85.2, -28.5). AEs occurred in 58.0% of linagliptin patients (serious AEs in 2.4%) and 58.2% of placebo patients (serious AEs in 3.0%).\ud \ud CONCLUSIONS:\ud This study was limited by the post hoc nature of the analysis, and because the pooling did not differentiate between geographically distant Asian regions. Nonetheless, this analysis provides evidence that linagliptin was efficacious and well tolerated as monotherapy or added to other oral antidiabetes therapies in Asian patients with T2DMKeywords
This publication has 34 references indexed in Scilit:
- Challenges in achieving optimal glycemic control in type 2 diabetes patients with declining renal function: The Southeast Asia perspectiveJournal of Diabetes Investigation, 2012
- Cardiovascular Biology of the Incretin SystemEndocrine Reviews, 2012
- Hypoglycemic symptoms in patients with type 2 diabetes in Asia-Pacific—Real-life effectiveness and care patterns of diabetes management: The RECAP-DM studyDiabetes Research and Clinical Practice, 2010
- Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitorsJournal of the American Pharmacists Association, 2009
- Diabetes in AsiaJama-Journal Of The American Medical Association, 2009
- Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2009
- Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real‐Life Effectiveness and Care Patterns of Diabetes Management (RECAP‐DM) StudyDiabetes, Obesity and Metabolism, 2008
- Pathophysiologic heterogeneity in the development of type 2 diabetes mellitus in Korean subjectsDiabetes Research and Clinical Practice, 2005
- Low risk threshold for acquired diabetogenic factors in Asian IndiansDiabetes Research and Clinical Practice, 2004
- Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitusMetabolism, 2001